Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins

Victoria Rollason, Médéric Mouterde, Youssef Daali, Martina Čížková, Edita Priehodová, Iva Kulichová, Helena Posová, Jitka Petanová, Anwar Mulugeta, Eyasu Makonnen, Abir Al-Habsi, Robin Davidson, Khalid K Al-Balushi, Khalid Al-Thihli, Marie Cerná, Said Al-Yahyaee, Viktor Černý, Getnet Yimer, Estella S Poloni, Jules Desmeules, Victoria Rollason, Médéric Mouterde, Youssef Daali, Martina Čížková, Edita Priehodová, Iva Kulichová, Helena Posová, Jitka Petanová, Anwar Mulugeta, Eyasu Makonnen, Abir Al-Habsi, Robin Davidson, Khalid K Al-Balushi, Khalid Al-Thihli, Marie Cerná, Said Al-Yahyaee, Viktor Černý, Getnet Yimer, Estella S Poloni, Jules Desmeules

Abstract

INTRODUCTION AND OBJECTIVE: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations.

Materials and methods: The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes' concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events.

Results: A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system.

Conclusions: In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.

Conflict of interest statement

Victoria Rollason, Médéric Mouterde, Youssef Daali, Martina Čížková, Edita Priehodová, Iva Kulichová, Helena Posová, Jitka Petanová, Anwar Mulugeta, Eyasu Makonnen, Abir Al-Habsi, Robin Davidson, Khalid K. Al-Balushi, Khalid Al-Thihli, Marie Cerná, Said Al-Yahyaee, Viktor Černý, Getnet Yimer, Estella S. Poloni, and Jules Desmeules have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Plasma concentration of each probe at the 2-h sampling time

References

    1. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005;360(1460):1563–1570. doi: 10.1098/rstb.2005.1685.
    1. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093–1108. doi: 10.1007/s00216-008-2291-6.
    1. Elewa H, Wilby KJ. A review of pharmacogenetics of antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet. 2017;42(5):745–756. doi: 10.1007/s13318-016-0399-1.
    1. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26(2):180–185. doi: 10.1097/00007691-200404000-00017.
    1. de Andrés F, Lerena LA. Simultaneous determination of cytochrome P450 oxidation capacity in humans: a review on the phenotyping cocktail approach. Curr Pharm Biotechnol. 2016;17(13):1159–1180. doi: 10.2174/1389201017666160926150117.
    1. Bosilkovska M, Samer C, Déglon J, Thomas A, Walder B, Desmeules J, et al. Evaluation of mutual drug-drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method. Basic Clin Pharmacol Toxicol. 2016;119(3):284–290. doi: 10.1111/bcpt.12586.
    1. Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, et al. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349–359. doi: 10.1038/clpt.2014.83.
    1. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. . Accessed 29 Apr 2020.
    1. Bosilkovska M, Clément M, Dayer P, Desmeules J, Daali Y. Incorporation of flurbiprofen in a 4-drug cytochrome p450 phenotyping cocktail. Basic Clin Pharmacol Toxicol. 2014;115(5):465–466. doi: 10.1111/bcpt.12231.
    1. Lloret-Linares C, Bosilkovska M, Daali Y, Gex-Fabry M, Heron K, Bancila V, et al. Phenotypic assessment of drug metabolic pathways and P-glycoprotein in patients treated with antidepressants in an ambulatory setting. J Clin Psychiatry. 2018;79(2):16m11387. doi: 10.4088/JCP.16m11387.
    1. Lloret-Linares C, Rollason V, Lorenzini KI, Samer C, Daali Y, Gex-Fabry M, et al. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacol Res. 2017;118:104–110. doi: 10.1016/j.phrs.2016.07.002.
    1. Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(Pt 1):585–648. doi: 10.1016/j.fct.2017.04.002.
    1. Kuate C, Gélisse P, Baldy-Moulinier M, Crespel A. Bupropion-induced epileptic seizures. Rev Neurol (Paris). 2004;160(6–7):701–703. doi: 10.1016/S0035-3787(04)71021-8.
    1. Goren JL, Levin GM. Mania with bupropion: a dose-related phenomenon? Ann Pharmacother. 2000;34(5):619–621. doi: 10.1345/aph.19313.
    1. Laib AK, Brünen S, Pfeifer P, Vincent P, Hiemke C. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther Drug Monit. 2014;36(4):473–479. doi: 10.1097/FTD.0000000000000042.
    1. Hamdy RC, Bird A, Le Gallez P, Hill J, Hind ID. A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. Eur J Clin Pharmacol. 1990;39(3):267–270. doi: 10.1007/BF00315108.
    1. Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev. 2007;13(1):96–106. doi: 10.1111/j.1527-3458.2007.00006.x.
    1. Franken LG, de Winter BCM, Masman AD, van Dijk M, Baar FPM, Tibboel D, et al. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br J Clin Pharmacol. 2018;84(2):320–330. doi: 10.1111/bcp.13442.
    1. Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(6):715–728. doi: 10.1038/clpt.1992.84.
    1. Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003;112(4 Suppl.):S69–S77. doi: 10.1016/S0091-6749(03)01879-7.
    1. Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009;5(7):813–822. doi: 10.1517/17425250903044967.
    1. Forgerini M, Mieli S, de Mastroianni PC. Safety assessment of omeprazole use: a review. Sao Paulo Med J. 2018;136(6):557–570. doi: 10.1590/1516-3180.2018.0019220318.
    1. Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986;32(1):15–47. doi: 10.2165/00003495-198632010-00002.

Source: PubMed

3
購読する